QIA Leads $250M Financing in Kardium to Support Commercial Launch

Bain Capital Invests up to $300M in Cardurion Pharmaceuticals

October 27, 2021

Biotechnology

Cardurion Pharmaceuticals, a clinical‑stage biotechnology company focused on cardiovascular therapeutics, received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity to advance its PDE9 and CaMKII inhibitor programs and to scale the business. The funding will support a major Phase 2 heart‑failure trial, initiation of first‑in‑human studies, and company growth; Bain Capital will also join Cardurion’s board alongside existing investors Takeda Pharmaceuticals and Polaris Partners.

QIA Takes Minority Stake in Kokusai Electric Corporation

June 22, 2023

Manufacturing

Qatar Investment Authority (QIA), via its subsidiary Qatar Holding LLC, has taken a minority stake in Japan-based semiconductor equipment manufacturer Kokusai Electric Corporation, acquiring shares from global investment firm KKR. The investment supports Kokusai's role in advanced deposition and treatment equipment amid rising demand from data centers, AI and other high-growth semiconductor end markets.

Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences

March 25, 2024

Biotechnology

Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.

Integer Holdings Acquires Pulse Technologies for $140M

January 5, 2024

Medical Devices

Integer Holdings Corporation has acquired Pulse Technologies, a Quakertown, Pennsylvania-based contract manufacturer of complex micro-machined medical device components, for approximately $140 million. The acquisition expands Integer's end-to-end development capabilities and manufacturing footprint in high-growth structural heart, neuromodulation and electrophysiology markets and brings roughly 250 Pulse employees into Integer.

Thoma Bravo Makes Strategic Growth Investment in Circle Cardiovascular Imaging

April 20, 2022

Healthcare Services

Thoma Bravo completed a strategic growth investment in Circle Cardiovascular Imaging (Circle CVI) to accelerate product innovation and expand the company's global market presence. Circle CVI, a Calgary-based provider of AI-driven cardiac imaging and reporting software used by hospitals and academic institutions in over 50 countries, will receive operational and financial support to drive future growth; financial terms were not disclosed.

Quadria Capital Leads $102M Investment in NephroPlus; Investcorp Partially Exits

May 7, 2024

Healthcare Services

Quadria Capital led a $102 million funding round in NephroPlus that combines primary capital and a secondary purchase of stakes from existing investors, including Investcorp, Bessemer Venture Partners, IFC and IIFL Private Equity. Investcorp retains a significant minority stake; the new capital will be used to fund organic growth in India and further international expansion of NephroPlus, Asia's largest dialysis service network headquartered in Hyderabad.